# ASTEPRO — FDA application NDA022203

Informational only - not investment advice.

Application NDA022203 · type NDA · FDA status: approved · original approval 2008-10-15

Listed sponsor: VIATRIS · [VTRS company profile](/company/VTRS/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | ASTEPRO | AZELASTINE HYDROCHLORIDE | SPRAY, METERED | NASAL | 0.137MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | Discontinued | not listed | Yes |
| 002 | ASTEPRO | AZELASTINE HYDROCHLORIDE | SPRAY, METERED | NASAL | 0.2055MG/SPRAY | Discontinued | not listed | No |

## Orange Book patent and exclusivity listings

- Patent 8071073, product 001; listed patent expiry date: 2028-06-04.
- Patent 8071073, product 002; listed patent expiry date: 2028-06-04.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- AZELASTINE HYDROCHLORIDE · UNII not resolved · no lmmol compound match

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/VTRS/)
- [FDA-approved application index](/drug/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA022203. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.